SOX11-Related Neurodevelopmental Disorder

1. Disease Information

1.1 Concise overview

SOX11-related neurodevelopmental disorder (commonly "SOX11 syndrome") is an autosomal dominant, congenital-onset neurodevelopmental disorder caused by heterozygous loss-of-function of SOX11, a single-exon SRY-related HMG-box (SoxC) transcription factor at 2p25.2. The core phenotype is developmental delay/intellectual disability with microcephaly, growth restriction, and mild fifth-digit/nail anomalies, with three distinguishing features that separate it from classical Coffin-Siris syndrome: oculomotor apraxia, structural ocular malformations (coloboma, microphthalmia, lens anomalies), and hypogonadotropic hypogonadism.

The disorder's nosology has shifted materially since 2014. It was first reported as Coffin-Siris syndrome (CSS) and assigned CSS9/OMIM 615866, because SOX11 is a transcriptional target downstream of the PAX6–BAF complex. The 2022 large-cohort study reclassified it as a distinct clinical and molecular entity, supported by a unique peripheral-blood DNA methylation episignature that separates it from the BAFopathies.

[VERBATIM — PMID:35341651, Al-Jawahiri et al., Genet Med 2022;24(6):1261–1273, DOI 10.1016/j.gim.2022.02.013] Purpose: "This study aimed to undertake a multidisciplinary characterization of the phenotype associated with SOX11 variants." Methods: "Individuals with protein altering variants in SOX11 were identified through exome and genome sequencing and international data sharing. Deep clinical phenotyping was undertaken by referring clinicians. Blood DNA methylation was assessed using Infinium MethylationEPIC array. The expression pattern of SOX11 in developing human brain was defined using RNAscope." Results: "We reported 38 new patients with SOX11 variants. Idiopathic hypogonadotropic hypogonadism was confirmed as a feature of SOX11 syndrome. A distinctive pattern of blood DNA methylation was identified in SOX11 syndrome, separating SOX11 syndrome from other BAFopathies." Conclusion: "SOX11 syndrome is a distinct clinical entity with characteristic clinical features and episignature differentiating it from BAFopathies."

[VERBATIM — PMID:37558216, Pasquetti et al., Clin Genet 2024, DOI 10.1111/cge.14414] "SOX11 variants were initially reported to cause Coffin-Siris syndrome (CSS), characterised by growth restriction, moderate ID, coarse face, hypertrichosis and hypoplastic nails. However, recent studies have provided evidence that they give rise to a distinct neurodevelopmental disorder." "…we made a confirmation that overall SOX11 abnormalities feature a distinctive disorder characterised by severe ID, high incidence of microcephaly and low frequency of congenital malformations."

1.2 Key identifiers

Recommendation for the dismech entry: use MONDO:0100626 as disease_term (its label is a near-exact match for the entry name "SOX11-Related Neurodevelopmental Disorder", and it is the term the ClinGen Intellectual Disability and Autism GCEP used for its Definitive gene-disease validity assertion). Carry MONDO:0014376 and OMIM:615866 in mappings.

1.3 Synonyms and alternative names

• SOX11 syndrome (preferred in the recent literature; Al-Jawahiri 2022, 2023)
• SOX11-related disorder (proposed as an umbrella framework: PMID:42168980)
• Coffin-Siris syndrome 9 / CSS9 (historical; still widely used in Chinese-language reports)
• Coffin-Siris syndrome-like syndrome (CSSLS) (used in the hESC modelling literature, PMID:31035284)
• Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism (IDDMOH) (current OMIM title)
• Mental retardation, autosomal dominant 27 / MRD27 (historical, discouraged)
• Autosomal dominant non-syndromic intellectual disability 27 (DOID synonym, misleading — the disorder is syndromic)

1.4 Provenance of the knowledge base

Information is overwhelmingly aggregated disease-level, derived from: 1. Genotype-first research cohorts — Deciphering Developmental Disorders (DDD) study exomes, the 100,000 Genomes Project, and GeneMatcher-mediated international data sharing (PMID:35341651). This is important: ascertainment is genotype-first, not phenotype-first, which reduces the phenotype-bias that inflated the early "Coffin-Siris" framing. 2. Targeted phenotype-first cohorts — a 1,810-proband idiopathic hypogonadotropic hypogonadism (IHH) cohort at Massachusetts General Hospital (PMID:39290158), and a 79-patient microphthalmia/anophthalmia/coloboma (MAC) cohort (PMID:25010521). 3. Registry data — the CSS/BAF registry (n=284, of whom 10 carried SOX11 variants; PMID:35126043). 4. Individual case reports — a substantial and growing set, disproportionately from China, expanding the organ-anomaly spectrum. 5. Curated databases — ClinGen (dosage + validity), ClinVar, DECIPHER, MGI.

No EHR-derived / individual-patient-level data source exists for this disorder. There is no patient registry, no natural-history study, and no OMOP/EHR phenotype algorithm published. This is a genuine gap.

1.5 NEC preflight and identifier discrepancies

NEC preflight (per dismech CLAUDE.md §2b): - ✅ Gene check. MONDO:0100626 and MONDO:0014376 both name SOX11 as causal; the dominant gene across all retrieved literature is SOX11. No competing gene dominates. - ✅ OMIM check. MONDO:0014376 xrefs OMIM:615866, matching every source. MONDO:0100626 does not carry an OMIM xref (it is a ClinGen/GARD-grounded term) but its includedPhenotype is MIM:615866 per ClinGen. - ⚠️ NEC-risk class flag. This disorder sits in two high-NEC-risk classes from research/nec_risk_disease_classes.md: (a) a numbered series — "Coffin-Siris syndrome 9" is one of ≥14 numbered CSS entries, and (b) a paralog family series — SOX4-related NDD (PMID:30661772, 35232796), SOX11, and SOX12 (PMID:39057025) are three closely-related SoxC disorders that are easily conflated. Also note MRD27 ≠ MRD-any-other-number. Curators should double-check that any deep-research report is about SOX11, not SOX4, and not a different CSS number (e.g. ARID1B=CSS1, SMARCB1=CSS3, ARID1A=CSS2).

Discrepancies found — flag for curator resolution:

2. Etiology

2.1 Disease causal factors

Monogenic, genetic, and essentially exclusively so. The disorder is caused by heterozygous loss-of-function of SOX11 through two mechanisms:

1. Intragenic single-nucleotide variants (SNVs) — predominantly missense variants clustered in or adjacent to the HMG DNA-binding domain, plus protein-truncating variants (PTVs). SNVs account for ~89% of reported cases (34/38 in the largest cohort).
2. Whole-gene / contiguous deletions of 2p25.2 encompassing SOX11 — ~11% (4/38 in Al-Jawahiri; 7 deletion cases in Hempel 2016; the index observation was a de novo 1.1 Mb deletion, PMID:18992374).

The unifying mechanism is haploinsufficiency — reduced SOX11 transcriptional dosage during embryonic and early postnatal development. This is supported at four independent levels:

[VERBATIM — PMID:31035284, Turan et al., Hum Mol Genet 2019, DOI 10.1093/hmg/ddz089] "Surprisingly, heterozygous missense mutations or deletions of SOX11 were recently detected in patients with Coffin-Siris syndrome-like syndrome (CSSLS), a neurodevelopmental disorder associated with intellectual disability, demonstrating that in humans SOX11 haploinsufficiency cannot be compensated and raising the question of the function of SOX11 in human neurodevelopment." "SOX11 haploinsufficiency impaired the generation of neurons and resulted in a proliferation/differentiation imbalance of neural precursor cells and enhanced neuronal cell death."

[VERBATIM — PMID:40832700, Baccas & Liu, G3 2025, DOI 10.1093/g3journal/jkaf194] "All the phenotypes observed in sem-2[Y160C] animals resemble SEM-2 loss-of-function phenotypes, suggesting that SOX11[Y116C] is a loss-of-function, recessive mutation that likely causes defects due to haploinsufficiency."

ClinGen dosage curation (evaluated 2024-11-21): haploinsufficiency score 3 — "Sufficient Evidence for Haploinsufficiency"; triplosensitivity score 0 — "No Evidence for Triplosensitivity". Cited evidence: PMID:18992374, 26543203, 24886874, 35341651, 39333428. ClinGen gene-disease validity (Intellectual Disability and Autism GCEP, reported 2025-05-20): Definitive, autosomal dominant, for MONDO:0100626.

Important negative — dominant-negative mechanism is not supported. The C. elegans data above show the disease-associated Y116C behaves recessively (homozygous, not heterozygous, animals are affected), which argues against a dominant-negative mode and for pure dosage insufficiency. Nuclear localisation of missense mutants is preserved (PMID:35938035), also arguing against a sequestration/dominant-negative model:

[FULL-TEXT — PMID:35938035] "The WT and two missense mutant SOX11 protein localized in the nucleus."

2.2 Risk factors

Genetic risk factors — causal variants (the only established risk factor): - De novo heterozygous SOX11 SNVs (missense >> PTV) and 2p25.2 deletions. - Parental germline/somatic mosaicism is a documented, non-negligible mechanism: "We identified 1 instance of transmission from a mosaic mother. This shows that recurrence could be possible due to mosaicism." [FULL-TEXT, Al-Jawahiri 2022 p.1267] - Inherited variants from a mildly affected parent occur: Al-Jawahiri identified "2 affected sibships (4 participants) [that] had a parent with ID who was presumed to be a SOX11 variant heterozygote (but was not tested)" [FULL-TEXT p.1263], and Hanker et al. documented confirmed maternal transmission (PMID:33785884).

Genetic risk factors — susceptibility loci / modifier genes: None established. No GWAS applies (this is a Mendelian disorder). One study reported an association of SOX11 distal 3′UTR polymorphisms with schizophrenia susceptibility (PMID:32207210), but this is a separate common-disease association with no established relevance to the Mendelian syndrome and should not be curated as a modifier of SOX11 syndrome.

Potential modifier — second genetic hits. Al-Jawahiri identified co-occurring variants in three probands (a BPTF variant, an IVD variant, a KATB [likely KAT6B] variant, all ACMG class 3) [FULL-TEXT p.1263], and PMID:35938035 found "a 4,300 kb deletion involving the region of 1q24.2-q25.1 … in patient 1, which also contributes to the condition of the patient" [VERBATIM]. Dual diagnoses do occur and complicate phenotype attribution — a curation caveat, not a modifier gene.

Environmental risk factors: None identified. No toxin, occupational, radiation, dietary, maternal-exposure, or lifestyle risk factor has been reported. Advanced paternal age is a general risk factor for de novo mutation across NDDs but has not been specifically demonstrated for SOX11. Sex is not a risk factor for occurrence (see §9). No association with consanguinity (the disorder is dominant).

2.3 Protective factors

None identified — genetic or environmental. No protective SOX11 alleles, no modifier alleles reducing severity, no dietary or lifestyle exposure shown to reduce risk or severity. Note the inverse of a protective genetic factor: functional redundancy among the SoxC paralogs (SOX4, SOX11, SOX12) was expected to buffer SOX11 loss but demonstrably does not in humans (PMID:31035284, quoted above) — a mechanistically informative negative.

2.4 Gene–environment interactions

No gene–environment interaction has been reported for this disorder. CTD and GxE resources contain no relevant SOX11 disease-modifier entries. The single mechanistically plausible (but entirely unstudied) GxE axis worth flagging as a knowledge gap is nutritional/catabolic status × growth-hormone deficiency, since GH deficiency and short stature are established features (PMID:39290158) and nutritional support is a standard CSS intervention.

3. Phenotypes

3.1 Frequency table — primary cohort (Al-Jawahiri 2022, n=38 new patients unless stated)

All numbers in this table are [FULL-TEXT] from the CC-BY published PDF, pp.1265–1266, except where a different source is cited.

3.2 Facial gestalt (HPO suggestions, from the OMIM/MedGen clinical synopsis + reports)

Short palpebral fissures (HP:0012745), depressed nasal bridge (HP:0005280), midface retrusion (HP:0011800), long nose (HP:0003189), anteverted nares (HP:0000463), short philtrum (HP:0000322), high palate (HP:0000218), thick vermilion border (HP:0012471), everted lower lip vermilion (HP:0000232), full cheeks (HP:0000293), long eyelashes (HP:0000527), low-set ears (HP:0000369), posteriorly rotated ears (HP:0000358), prominent forehead (HP:0011220), arched eyebrow (HP:0002553), broad nasal tip (HP:0000455), wide mouth (HP:0000154).

Curation caution (from the source itself): "The facial dysmorphic features seem not to be specific" [VERBATIM, PMID:33785884]. Do not over-weight facial features.

3.3 Behavioural phenotype (quantitatively characterised — n=21)

[VERBATIM — PMID:37924570, Al-Jawahiri et al., Res Dev Disabil 2023, DOI 10.1016/j.ridd.2023.104623] "Most participants demonstrated borderline (33%) or mild (39%) adaptive behavior impairment, with greater communication and daily-living difficulties than social challenges. Ninety percent exhibited clinically significant autistic traits, with 62% in the 'severe' range, though social motivation emerged as a relative strength. This represents the first standardized evaluation of adaptive behavior and autistic characteristics in SOX11 syndrome populations."

The pattern — communication and daily-living deficits exceeding social deficits, with intact social motivation — is a genuinely distinguishing behavioural signature and is worth curating explicitly, because it separates SOX11 syndrome from idiopathic ASD.

3.4 Phenotype characteristics: onset, severity, progression

• Onset: congenital / prenatal (IUGR, structural malformations) and infantile (developmental delay). Endocrine features declare themselves in adolescence (delayed puberty). HPO onset: HP:0003577 Congenital onset / HP:0003593 Infantile onset.
• Severity: highly variable — "Cognitive outcomes range from profound intellectual disability (ID) to low normal IQ, with most individuals having moderate ID" [VERBATIM, PMID:38117302]. Note that PMID:38117302 is a mixed BAFopathy adult cohort including SOX11.
• Progression: the neurodevelopmental core is static/non-progressive (developmental, not degenerative). Skeletal (scoliosis), ophthalmological (myopia), endocrine (pubertal failure), and metabolic (obesity) features are progressive/emergent with age.
• Frequency among affected individuals: see §3.1.

3.5 Quality-of-life impact (per phenotype)

No disease-specific QoL instrument (EQ-5D, SF-36, PROMIS) has been administered in a SOX11 cohort. This is an explicit gap. Functionally-inferred impact:

4. Genetic / Molecular Information

4.1 Causal gene

SOX11 — SRY-box transcription factor 11.

[VERBATIM — NCBI Gene 6664 RefSeq summary] "This intronless gene encodes a member of the SOX (SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development and in the determination of the cell fate."

[FULL-TEXT — Al-Jawahiri 2022 p.1262] "SOX11 is a single exon gene with a single transcript, which is predicted to be haploinsufficient and loss-of-function intolerant."

Curation consequence of intronlessness: there are no canonical splice-site variants in SOX11. Any deep-research report asserting a SOX11 splice variant is a red flag. A single exon also means intragenic deletions are rare and whole-gene deletions predominate among CNVs.

4.2 Pathogenic variant spectrum

Cohort composition (Al-Jawahiri 2022, [FULL-TEXT p.1263]): - 38 new patients: 34 SNVs + 4 deletions - 29 distinct SNVs: 25 unique missense + 4 protein-truncating variants (PTVs) - One sibling pair shared a PTV; one sibling pair shared a missense variant - All 4 PTVs classified pathogenic; of the missense variants, 5 likely pathogenic and 20 pathogenic - De novo confirmed in 30 patients; 1 inherited from a mosaic parent; 2 sibships (4 participants) with a presumed-heterozygous affected parent - Plus 15 previously published patients with SOX11 SNVs

Cumulative published tally: ~82 individuals with SOX11 variants reported in the literature as of the Pasquetti 2024 review [VERBATIM: "32 out of 82 subjects reported in the literature with SOX11 variants"]; 56 distinct variants catalogued by Wu et al. 2024 [VERBATIM: "Analysis of 56 SOX11 variants…"]; 30 unique variants in the HH-focused review [VERBATIM, PMID:42168980: "Thirty unique variants were identified, 17/30 clustering within the HMG domain and 15/18 proven de-novo"].

4.3 Variant catalogue (published, protein-level, with source)

Within/flanking the HMG box (aa 48–119) — the mutational hotspot. From Al-Jawahiri 2022 Figure 1, aggregating published + novel:

His48Asp · Ile49Asn · Lys50Asn (recurrent, ≥3×) · Lys50Gln · Gly47Ser (recurrent, ≥3×) · Arg51Leu · Arg51Gln · Arg51Gly · Arg51Trp · Arg51Pro · Pro52Ser · Pro52Leu · Met53Arg · Met53Ile · Met53Val · Ala55Thr (recurrent) · Phe56Leu · Met57Thr · Trp59* · Ser60Pro · Arg64Leu · Arg64Cys · Arg64Pro · His75Asp · Ser80Phe · Ile79Val · Gly84Ser · Gly84Val · Ala86AlafsTer139 · Arg86TerfsTer13 · Trp87Arg (recurrent) · Phe98Leu · Ala102Val · Arg106Pro · His109Asn · His109Pro · His109Tyr · Tyr113His · Tyr116Cys (recurrent) · Tyr116del · Pro120His

Outside the HMG box: Cys29* · Ala142Gly · Ala174ArgfsTer32 · Ala176Glu · Asp223MetfsTer45 · Asn271SerfsTer10 · Lys274* · Tyr294* · Glu324* · Ser338Leu · Gly384ArgfsTer14

cDNA-level variants with confirmed source attribution:

4.4 Variant classification (ACMG/AMP)

Al-Jawahiri classified all 29 SNVs using ACMG/AMP criteria via VarSome: all 4 PTVs pathogenic; 20 missense pathogenic; 5 missense likely pathogenic. Two novel lines of evidence supported missense classification:

1. Paralogue-based evidence (PP-level). "There is significant sequence homology between the HMG box domains of human SOX proteins. We reasoned that if pathogenic variants had been reported at a given residue in a SOX protein, then it could be taken as possible evidence of pathogenicity for the equivalent variant in SOX11. … In total, 6 residues in SOX11 had pathogenic variants (DECIPHER and ClinVar) at equivalent residues in SOX10. Several of these had identical amino acid change, eg, p.(Arg51Gly) in SOX11 and p.(Arg106Gly) in SOX10." [FULL-TEXT p.1264]
2. Domain-level constraint (PM1-level). "we identified that the percentage of residues with a missense SNV in the HMG box was significantly lower than in the N-terminal, central, or transactivating domains." [FULL-TEXT p.1264]

Curator caution from the source itself: "It should not be assumed that all HMG box missense variants are pathogenic." [FULL-TEXT p.1263–64]

ClinVar (as of retrieval): the ClinVar search interface did not render usable counts via WebFetch. Curators must obtain the ClinVar breakdown directly (SOX11[gene]) rather than relying on this report. Example pathogenic variants are catalogued in §4.3 above with primary-literature attribution.

4.5 Variant type / class distribution

4.6 Population constraint and allele frequency

[FULL-TEXT — Al-Jawahiri 2022 p.1264] "none of the SOX11 missense variants were present in Genome Aggregation Database (gnomAD), and only 8 HMG missense variants in SOX11 were identified in 114,704 individuals in gnomAD v2.1.1 non-neuro data set. This strongly suggests that missense variants in this domain are not compatible with normal neurodevelopment." "Only 2 PTVs are present in gnomAD (v2.1.1 non-neuro data set), and SOX11 is predicted to be loss-of-function intolerant with probability of loss of function intolerance = 0.86 (observed/expected 0.09 [0.03-0.44])."

So: gnomAD v2.1.1 → pLI = 0.86, o/e LoF = 0.09, LOEUF (upper CI) = 0.44.

⚠️ Discrepancy D4. A web search snippet asserted gnomAD v4 values of pLI 0.09 / LOEUF 1.15 for SOX11. I could not verify this — the gnomAD browser is JavaScript-rendered and its GraphQL API requires POST, both inaccessible to the fetch tooling available here. The snippet's "0.09" is suspiciously identical to the published o/e LoF, suggesting a garbled transcription. Do not curate the v4 numbers from this report. Curate the published v2.1.1 values with their PMID, and if gnomAD v4 constraint is wanted, query gnomAD directly.

Mechanistic caveat worth recording regardless: SOX11 is a 441-aa single-exon gene, so its expected pLoF count is very small and LoF-constraint metrics are intrinsically low-powered for it. The authoritative dosage statement is therefore ClinGen haploinsufficiency score 3, not any LOEUF value.

Allele frequency of pathogenic variants: effectively zero. All are absent from gnomAD, 1000 Genomes, ExAC, and TOPMed. This supports PM2 for every reported variant.

4.7 Somatic vs germline origin

• Germline for the neurodevelopmental disorder — overwhelmingly de novo (30/38 confirmed).
• Parental mosaicism documented once (mosaic mother, Al-Jawahiri 2022).
• Somatic SOX11 aberration is a completely separate biology and must not be conflated with the NDD. SOX11 is not somatically mutated as a cancer driver; it is aberrantly over-expressed:
• Mantle cell lymphoma — SOX11 over-expression is an established diagnostic biomarker and oncogene; it distinguishes conventional nodal MCL from indolent leukaemic non-nodal MCL, and drives pathogenesis in part via SOX11–SMARCA4 complex formation.
• Adrenergic neuroblastoma — recurrent 2p focal gains and amplifications of SOX11: > [VERBATIM — PMID:36882421, Decaesteker et al., Nat Commun 2023, DOI 10.1038/s41467-023-36735-2] "Most notably, SOX11 controls chromatin regulatory complexes, including 10 SWI/SNF core components among which SMARCC1, SMARCA4/BRG1 and ARID1A. … Finally, SOX11 is identified as a core transcription factor of the core regulatory circuitry (CRC) in adrenergic high-risk neuroblastoma with a potential role as epigenetic master regulator upstream of the CRC."

Note the striking directional inversion this creates: in the germline NDD, SOX11 sits downstream of the PAX6–BAF complex; in neuroblastoma, SOX11 sits upstream of and regulates the SWI/SNF components (SMARCA4, ARID1A) whose germline loss causes the other Coffin-Siris subtypes. This reciprocal SOX11↔BAF relationship is worth curating as a mechanistic note.

Important negative: no cancer predisposition has been reported in individuals with germline SOX11 variants. Do not import oncological surveillance into the NDD entry. (Contrast ARID1A-CSS, which does carry a hepatoblastoma AFP-surveillance recommendation.)

4.8 Functional consequences

Loss of function via two structurally distinct routes, both experimentally validated by GDF5-promoter luciferase assay:

[FULL-TEXT — Al-Jawahiri 2022, Figure 2 legend + p.1265] "Luciferase assay showing impaired activation of GDF5 promoter by G384Rfs14, A176E, and Y294 SOX11 variants. A176E impairs SOX11 activity but to a much lesser extent than Y294 or G384Rfs14." "In vitro analysis of 2 PTVs showed significant impairment of SOX11 transactivating activity. … The mechanism through which PTV leads to reduction in SOX11 transactivating activity may relate to the loss of C-terminal transactivation domain."

• HMG-box missense → impaired DNA binding → reduced target-gene transactivation. Four previously-characterised HMG variants (p.Lys50Asn, p.Pro120His, p.Ser60Pro, p.Tyr116Cys) impair transactivation. Nuclear import is preserved (PMID:35938035) — so the defect is at the DNA-binding/transactivation step, not trafficking.
• PTV → loss of the C-terminal TAD (aa 408–441) → near-complete loss of transactivation.
• Non-HMG missense can also be pathogenic but with a milder biochemical deficit: p.Ala176Glu "significantly reduced SOX11 transactivating activity … but to a much lesser extent." Notably this milder-in-vitro variant occurred in the most severely affected patient (case 11: neonatal death, cerebellar hypoplasia, microcephaly) — in-vitro residual activity does not predict clinical severity. Curate this as an explicit knowledge gap.
• Not dominant-negative — see §2.1.

Reporter/target genes used in functional assays: GDF5 (promoter −448/+319, NM_000557.3, GRCh37/hg19), the standard SOX11 reporter across three independent labs (PMID:26543203, 35341651, 35938035). Additional validated direct targets: FGF9 (palate/mandible; PMID:26826126), the protocadherin B cluster locus control region (kidney; PMID:29459093), the GNRH1 intron-A enhancer (PMID:21527504), hlh-8/Twist ortholog (C. elegans; PMID:40832700).

4.9 Modifier genes

None established. See §2.2 for the distinct issue of co-occurring second diagnoses.

4.10 Epigenetic information — the SOX11 episignature

This is one of the most curation-relevant features of the disorder and functions as a clinical diagnostic biomarker.

[FULL-TEXT — Al-Jawahiri 2022 pp.1263, 1265] "A total of 224 differentially methylated probes (DMPs) were identified and considered as the SOX11 episignature." "An overall hypomethylation pattern was observed for most probes when comparing 10 SOX11 cases … and control samples." "BAFopathy complex samples were applied to the SOX11 episignature classifier, but none of them were grouped with SOX11 samples." "Many of these DMPs have regulatory roles in neural differentiation and are associated with NDDs (ie, family with sequence similarity 160 member B1 [FAM160B1] and FMN2). Some DMPs have regulatory role in the epigenetic machinery, such as DPF2 and AHCTF1."

Methodology (for the dismech datasets/diagnostics sections): Illumina Infinium MethylationEPIC BeadChip on peripheral blood DNA; 10 SOX11 cases vs 50 age/sex/array-matched controls (5:1) drawn from the EpiSign Knowledge Database; β→M-value transformation; limma linear modelling; two binary SVM classifiers with linear kernel (e1071) generating a methylation variant pathogenicity (MVP) score 0–1; Platt scaling; 10-fold cross-validation on MDS.

Cross-reactivity to flag: in the first (less specific) classifier, "Some samples from other disorders that are in EKD that are part of the EpiSign V2 clinical assay, including autosomal dominant cerebellar ataxia, deafness, and narcolepsy, HVDAS_T, and Sotos syndrome, plus 1 sample from control (testing), Kabuki syndrome, and mental retardation, autosomal dominant type 51 cohorts showed an elevated MVP score." Training against 38 additional NDD/congenital-anomaly episignatures resolved this: "A high MVP score was seen in 10 SOX11 samples with much improved specificity relative to other EpiSign conditions."

4.11 Chromosomal abnormalities

• 2p25.2 microdeletions encompassing SOX11 — the founding observation was a de novo ~1.1 Mb deletion in a girl with ID, autism, and microcephaly (PMID:18992374, "Deletion 2p25.2: a cryptic chromosome abnormality in a patient with autism and mental retardation detected using aCGH"). Hempel 2016 identified 7 such individuals; Al-Jawahiri added 4. A segmental deletion encompassing SOX11 also produced "microphthalmia and related ocular phenotypes" (PMID:25010521).
• Detection: requires chromosomal microarray or CNV calling from exome/genome data. Because SOX11 is a single-exon gene, exome CNV callers with poor single-exon sensitivity may miss intragenic events — a real diagnostic pitfall to record.
• No translocations, inversions, or aneuploidies are associated with the germline disorder. (Contrast MCL's t(11;14) — a somatic event, unrelated.)

5. Environmental Information

Environmental factors: none identified. No toxin, pollutant, radiation, or occupational exposure has been implicated in causation or modification. CTD contains no SOX11 disease-modifier chemical interactions relevant to this disorder.

Lifestyle factors: none causal. Two lifestyle-adjacent items are relevant downstream, not upstream: 1. Adult overweight/obesity is frequent in molecularly-confirmed CSS adults including SOX11 carriers (PMID:38117302) — a management target, not an aetiological factor. 2. Nutritional/feeding support is a core intervention (PMID:23556151).

Infectious agents: not applicable. This is a Mendelian disorder with no infectious trigger. One tangential retrieval — PMID:41567998, "Neurogenesis decreases in the offspring of mothers infected with influenza A virus" (Front Cell Infect Microbiol 2026) — appeared in the SOX11 literature search because it examines Sox11-dependent neurogenesis pathways in a maternal-immune-activation model. This is not evidence of an infectious contribution to human SOX11 syndrome and should not be curated as such.

Curation guidance: the environmental_factors and infectious_agents sections of the dismech entry should be explicitly empty with a note, not silently omitted — the absence is informative for a purely genetic disorder.

6. Mechanism / Pathophysiology

6.1 Causal chain (upstream → downstream)

[TRIGGER — MOLECULAR]
Heterozygous SOX11 loss-of-function
  (HMG-box missense → impaired DNA binding;  PTV → loss of C-terminal TAD;
   whole-gene deletion → dosage loss)
│
▼
[MOLECULAR]  Reduced SOX11 transcriptional dosage
     → hypoactivation of SOX11 target genes
       (GDF5, FGF9, PCDHB-cluster LCR, GNRH1 intron-A enhancer, hlh-8/Twist)
     → NOT compensated by paralogues SOX4/SOX12 (PMID:31035284)
│
├──────────────────┬──────────────────┬────────────────┬──────────────┐
▼                  ▼                  ▼                ▼              ▼
[CELLULAR]           [CELLULAR]         [CELLULAR]      [CELLULAR]      [CELLULAR]
Neural precursor     Sensory neuron     Mandibular      Nephrogenic-    Hedgehog
proliferation/       survival ↓ and     mesenchyme      cord Gdnf       signalling
differentiation      axonal growth ↓    proliferation ↓ domain          DYSREGULATION
imbalance;           (inner ear)        via Cyclin D1   extended        (↑shha)
neuronal cell        │                  → FGF9 ↓        rostrally       │
death ↑              │                  │               │               │
│            │                  │               │               │
▼            ▼                  ▼               ▼               ▼
[TISSUE]        [TISSUE]           [TISSUE]         [TISSUE]        [TISSUE]
Reduced cerebral Cochlear nerve    Mandibular       Duplex kidney,  Failure of
+ cerebellar     aplasia/          hypoplasia →     malpositioned   choroid fissure
growth; corpus   hypoplasia        tongue mal-      kidney,         closure; lens
callosum         (structurally     position →       hydroureter;    dysgenesis;
agenesis         normal cochlea)   physical block   short Henle's   rod photo-
│            │             of palatal       loop            receptor loss
│            │             shelf elevation      │               │
▼            ▼                  ▼               ▼               ▼
[ORGANISM]      [ORGANISM]        [ORGANISM]       [ORGANISM]      [ORGANISM]
Microcephaly,   Unilateral        Cleft secondary  Renal anomalies Coloboma,
DD/ID, absent   sensorineural     palate           (~8%)           microphthalmia,
speech (~20%),  hearing loss      (Pierre Robin-                   high myopia
autistic traits (CI benefit                like)
 limited)

└─── PARALLEL ENDOCRINE ARM ───────────────────────────────┐
                                                   ▼
[CELLULAR]  SOX4/SOX11 fail to activate the GNRH1 intron-A enhancer in
    hypothalamic GnRH neurons;  SOX11 depleted in pituitary gonadotropes;
    ± failed GnRH-neuron migration from olfactory neuroepithelium
                                                   │
                                                   ▼
[TISSUE]    Olfactory bulb/nerve hypoplasia;  pituitary hypoplasia;
    small/absent adenohypophysis
                                                   │
                                                   ▼
[ORGANISM]  Hypogonadotropic hypogonadism (21%) ± anosmia (Kallmann phenotype);
    delayed puberty; GH deficiency; hypothyroidism

6.2 Molecular pathways

6.3 Cellular processes

All GO IDs above are suggestions requiring OAK verification (uv run runoak -i sqlite:obo:go info GO:XXXXXXX -O obo).

6.4 Protein dysfunction

SOX11 (441 aa, UniProt P35716) is a nuclear transcriptional activator with an HMG DNA-binding domain (aa 48–119) and a C-terminal TAD (aa 408–441).

[FULL-TEXT — Al-Jawahiri 2022 p.1263] "The HMG box in SOX11 protein is a domain responsible for SOX11 binding to DNA and regulation of target genes. In addition, the HMG box regulates key protein–protein interactions and trafficking of SOX11 protein between cytoplasm and nucleus."

Dysfunction modes: (i) reduced DNA-binding affinity (HMG missense); (ii) loss of transactivation capacity (PTV truncating the TAD); (iii) absent protein (whole-gene deletion). No misfolding, aggregation, or gain-of-function mechanism is described. Nuclear localisation is preserved for missense mutants.

Two additional regulatory layers of protein dysfunction, both post-translational:

[VERBATIM — PMID:30385877, Sci Rep 2018] "Through Mass Spectrometry (MS), co-immunoprecipitation assays and in vitro phosphorylation assays followed by MS we verified that protein kinase A (PKA) interacts with SOX11 and phosphorylates it on S133. In vivo replacement of SoxC factors in developing adult-generated hippocampal neurons with SOX11 S133 phospho-mutants indicated that phosphorylation on S133 modulates dendrite development of adult-born dentate granule neurons."

[VERBATIM — PMID:29973868, Front Mol Neurosci 2018] "Using Mass Spectrometry, we found 10 serine residues in the SOX11 protein that are putatively phosphorylated. Systematic analysis of phospho-mutant SOX11 resulted in the identification of the S30 residue, whose phosphorylation promotes nuclear over cytoplasmic localization of SOX11."

[VERBATIM — PMID:33579706, Chiang et al., Sci Adv 2021] "Mechanistically, these functions are mediated by a previously unidentified Usp11 substrate, Sox11. Usp11 ablation compromises Sox11 protein accumulation in the developing cortex, despite the induction of Sox11 mRNA. The disease-associated Usp11 mutant fails to stabilize Sox11 and is unable to support cortical neurogenesis and neuronal migration."

6.5 Metabolic changes

No primary metabolic defect. SOX11 syndrome is not an inborn error of metabolism. Secondary/endocrine-metabolic consequences: GH deficiency, hypothyroidism (PMID:39290158), and adult overweight/obesity (PMID:38117302). No metabolomic or lipidomic study exists.

6.6 Immune system involvement

None. No autoimmunity, immunodeficiency, or chronic inflammation is described. (SOX11's role in B-cell maturation arrest is a mantle cell lymphoma phenomenon — somatic over-expression — and does not manifest as immune dysfunction in germline SOX11 haploinsufficiency.)

6.7 Tissue damage mechanisms

Developmental hypoplasia/dysmorphogenesis, not tissue destruction. There is no oxidative stress, ischaemia, fibrosis, or necrosis mechanism. The one true cell-death mechanism is developmentally-timed apoptosis of neural precursors/neurons (PMID:31035284) and reduced sensory-neuron survival (PMID:35642566), both prenatal/perinatal. Two morphogenetic-obstruction mechanisms are unusual and worth explicit curation: 1. Cleft palate is secondary, not primary — mandibular hypoplasia mispositions the tongue, physically obstructing palatal-shelf elevation. The shelves themselves retain fusion competence (PMID:26826126). 2. Coloboma arises from excess Hedgehog signalling (a gain in a downstream pathway from a loss in the upstream factor) — rescued by the Hh inhibitor cyclopamine (PMID:25010521).

6.8 Epigenetic changes

Two distinct epigenetic dimensions: 1. The disease episignature — 224 DMPs with global hypomethylation in peripheral blood (§4.10). Diagnostic biomarker. 2. SOX11 as an epigenetic regulator — SOX11 regulates DPF2 and AHCTF1 (epigenetic machinery) among the DMP genes, and in neuroblastoma controls 10 SWI/SNF core components, HDAC2, CBX2 (PRC1), and KDM1A/LSD1. Al-Jawahiri's interpretation: "aberrations in the expression/methylation status of SOX11 affects expression/methylation status of genes involved in neural differentiation and/or epigenetic machinery" [FULL-TEXT p.1269].

Therapeutic implication flagged by the authors: "The plastic nature of epigenomic profiles may offer an opportunity to study the use of chromatin and epigenomic targeting agents as a potential therapeutic avenue." [FULL-TEXT p.1269] This is hypothesis-only.

6.9 Molecular profiling

Transcriptomics. SOX11 developmental brain expression confirmed by RNA-seq and microarray in the BrainSpan atlas; RNAscope ISH used for spatial confirmation (see §7). Downstream target genes identified by "functional genomics" in the mouse conditional-KO study (PMID:23483698). In zebrafish sox11a mutants, "the expression levels of genes related to cartilage and bone were downregulated" [VERBATIM, PMID:33061816]. No patient-tissue transcriptomic study exists.

Proteomics. Mass-spectrometry phospho-mapping of SOX11 (10 putative phospho-serines; S30, S133 functionally characterised) — PMID:30385877, 29973868. SOX11 interactome (SMARCA4) mapped in the MCL context. No patient-derived proteomic study.

Metabolomics / lipidomics. None. Genuine gap.

Epigenomics. The 224-DMP EPIC-array episignature (§4.10) — the single strongest omics dataset in this disorder.

Genomic structural features. Single-exon, intronless, 2p25.2, ~9 kb genomic span, single transcript. Regulated in cis by "multiple adrenergic specific (super-)enhancers" in neuroblastoma (PMID:36882421) — implying an enhancer landscape whose disruption is a plausible but unreported non-coding mechanism in the NDD. Worth curating as a knowledge gap: no non-coding/regulatory SOX11 variants have been reported in this disorder.

6.10 Advanced technologies

• Single-cell. "A single-cell RNA-sequencing study of murine pituitary showed significant enrichment of SOX11 in gonadotropes" (PMID:33430815-adjacent; ref 33 = Ho Y, Hu P, Peel MT et al., Protein Cell 2020;11(8):565–583) — the mechanistic anchor for pituitary-level HH. Counterpoint: "in an induced human pluripotent cell model of GnRH neurons, SOX11 expression was not enriched" (Lund C et al., Dis Model Mech 2020;13(3):dmm040105) — a genuine human/model discordance at the hypothalamic level. Also PMID:34184026 (scRNA-seq TCF4-dependent TF network in commissure development — the SOX11/TCF4 link relevant to the Pitt-Hopkins mimicry).
• Spatial transcriptomics. RNAscope ISH in human fetal tissue (Carnegie stages 20, 21, 23) — see §7. No true spatial-transcriptomics dataset.
• Multi-omics integration. PMID:41580083 (SLAS Technol 2026, "Integrative single-cell multi-omics network analysis to elucidate epigenetic regulation in neurodevelopmental disorders") includes SOX11-relevant network analysis.
• Functional genomics screens. SOX11 is a dependency gene in adrenergic neuroblastoma per CRISPR screening (PMID:36882421) — a cancer, not NDD, finding. No CRISPR/RNAi screen has been run in a SOX11-haploinsufficient neurodevelopmental model beyond the isogenic hESC line (PMID:31035284).
• Organoids. PMID:40950130 (bioRxiv 2025) — morphogen-guided neocortical organoids modelling NDD pathology, with regional areal identity; a promising but preprint-stage platform.

6.11 MorPhiC relevance

SOX11 is not among the MorPhiC anchor genes (ISL1, EOMES, GCM1, NKX2-1). However, the SOX11⁺/⁻ isogenic hESC line (PMID:31035284) is an exact methodological analogue — a CRISPR/Cas9 heterozygous null in human pluripotent cells with cellular-phenotype readouts. If curating category: Cellular phenotypes, use that paper with evidence_source: IN_VITRO:

7. Anatomical Structures Affected

7.1 Organ level

Primary (directly affected):

Secondary / complication-level: thyroid (hypothyroidism), skeletal system (scoliosis, growth restriction), gastrointestinal (feeding difficulty), adipose (adult obesity).

Body systems involved: nervous (primary), sensory/special-sense (eye, ear, olfaction), endocrine/reproductive, renal/urinary, craniofacial/skeletal, cardiovascular (uncommon), integumentary (nails, hypertrichosis).

7.2 Tissue and cell level

Cell types (CL suggestions — all require OAK verification):

Tissue types affected: nervous tissue (predominant), mesenchyme/connective tissue (craniofacial, skeletal), epithelium (renal tubule, lens, adenohypophysis).

7.3 Subcellular level

No mitochondrial, ER, lysosomal, or peroxisomal involvement.

7.4 Localization and lateralization

• Brain malformations are midline/bilateral (corpus callosum agenesis, arhinencephaly, cerebellar hypoplasia — bilateral). HPO: HP:0012832 Bilateral.
• Cochlear nerve deficiency is characteristically UNILATERAL in both reported probands (PMID:35642566) — a notable asymmetry. HPO: HP:0012833 Unilateral.
• Microtia was unilateral (PMID:38591849).
• Ocular coloboma may be uni- or bilateral; the CSS9 high-myopia case was bilateral.
• Renal anomalies: duplex/malpositioned kidney, typically unilateral in the mouse model.
• Olfactory bulb/nerve hypoplasia: bilateral (PMID:42168980).

Curation note: the combination of bilateral CNS midline defects with unilateral peripheral sensory-nerve and external-ear defects is an unusual laterality signature and merits explicit laterality/description capture.

7.5 Human fetal expression — the anchoring anatomical evidence

[FULL-TEXT — Al-Jawahiri 2022 pp.1266, 1268 (RNAscope ISH)] "ISH showed widespread expression of SOX11 in fetal cranial structures. … At all Carnegie stages examined, SOX11 was strongly expressed in the cerebral cortex and hindbrain. Expression within the developing retina and optic nerve was also noted, particularly in Carnegie stage 23. Of interest, SOX11 expression was noted in the developing pituitary, lining the lumen of the adenohypophysis, and also within the neurohypophysis. There was no clear difference observed in spatial localization between SOX11 expression and GnRHR expression." Figure 5: "SOX11 expression in frontal cortex (*), spinal cord (**), and palate (***)" at CS21 (~51 days post-conception); "SOX11 expression in developing eye at CS23 (~56 days post-conception) in lens (*), optic nerve (**), and neuroretina (***)"; "SOX11 expression in pituitary at CS20 (~49 days post-conception) lining lumen of adenohypophysis (*) and also in neurohypophysis (**)."

This is high-value evidence: each affected organ in the human phenotype has a matching human fetal SOX11 expression domain. Use it to justify the anatomical annotations directly.

8. Temporal Development

8.1 Onset

• Onset: congenital (HP:0003577). Structural malformations (coloboma, cleft palate, cardiac, renal, microcephaly, IUGR) arise during embryogenesis; the human fetal expression window documented by RNAscope is Carnegie stages 20–23, ~49–56 days post-conception. Developmental delay is recognised in infancy (HP:0003593 Infantile onset).
• Onset pattern: chronic / static developmental, not acute or episodic. No relapsing course.
• Prenatal detectability: IUGR and structural anomalies (TGA/Berry syndrome detected on prenatal imaging, PMID:42015706) can be prenatally apparent. One case died in the neonatal period (Al-Jawahiri case 11, p.Ala176Glu, with cerebellar hypoplasia and microcephaly) — perinatal lethality is possible but rare.

8.2 Progression

Disease stages (no formal staging system exists; the following is a natural-history synthesis):

• Progression rate: the neurodevelopmental core is non-progressive (static encephalopathy). Overlaid features (scoliosis, myopia, obesity, pubertal failure) are slowly progressive / age-emergent.
• Disease course pattern: stable/static with age-emergent comorbidity. Not episodic, not relapsing-remitting, not neurodegenerative.
• Duration: chronic lifelong.
• Cohort age range: "The mean age at examination was 9 years (range: neonate to 23 years)" [FULL-TEXT, Al-Jawahiri 2022 p.1265]. The adult cohort study (PMID:38117302) covers ≥18 y.

8.3 Patterns

• Remission: none — spontaneous or treatment-induced. No remission is possible for a developmental haploinsufficiency disorder. Partial reversal of one manifestation is achievable: GnRH-pump therapy "restored gonadotropin output within 72 h" [VERBATIM, PMID:42168980] — a pharmacological rescue of the downstream hormonal deficit, not disease remission.
• Critical periods:
• CS20–23 (~7–8 weeks post-conception) — the window of SOX11-dependent organogenesis. Irreversible once passed; the reason no disease-modifying therapy is conceivable postnatally for the malformation component.
• Infancy–early childhood (0–5 y) — the intervention window for speech, motor, and feeding therapy, where the ~20% risk of never attaining speech is determined.
• Adolescence (11–14 y) — the window for pubertal induction. Missing it costs bone density, growth, and psychosocial development. This is the single most actionable clinical window in the disorder.
• First years of life — cochlear-nerve imaging window; determines cochlear-implant candidacy (a CI is of limited benefit if the cochlear nerve is aplastic).

9. Inheritance and Population

9.1 Epidemiology

Prevalence: not established. No formal prevalence or incidence estimate exists for SOX11-related NDD. Neither Orphanet, GBD, CDC, WHO, nor any national registry publishes a rate. Recommend curating a Prevalence record with:

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No formal prevalence estimate published. Approximately 82 individuals with
    SOX11 variants had been reported in the literature as of the 2024 review
    (PMID:37558216); 56 distinct variants catalogued (PMID:38591849). Ultra-rare;
    ascertainment is genotype-first via research exome/genome cohorts.
  evidence:
  - reference: PMID:37558216
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "32 out of 82 subjects reported in the literature with SOX11 variants"
    explanation: >-
      Establishes the published case count as of 2024; no population rate is
      available for this disorder.

Denominator anchors that can be cited: - 10 / 284 individuals in the CSS/BAF registry carried SOX11 variants — i.e. SOX11 is the second-rarest cause among the CSS genes studied, ahead only of SMARCE1 (PMID:35126043; ARID1B 174, SMARCA4 41, ARID1A 20, SMARCB1 20, ARID2 14, SOX11 10, SMARCE1 5). - 5 / 1,810 unrelated IHH probands carried pathogenic SOX11 variants — ~0.28% of IHH (PMID:39290158). - 2 / 79 patients in a microphthalmia/anophthalmia/coloboma cohort carried novel heterozygous SOX11 variants — ~2.5% of MAC (PMID:25010521). - Al-Jawahiri's 38 patients were drawn from DDD + 100,000 Genomes Project + GeneMatcher, so SOX11 is a rare but recurrent finding in large-scale NDD sequencing.

Orphanet caveat: ORPHA:1465 covers Coffin-Siris syndrome as an umbrella. Because the field now treats SOX11 syndrome as a distinct entity, any ORPHA:1465 prevalence figure would be an over-estimate if applied to SOX11 alone. Do not import it.

9.2 Inheritance (genetic etiology)

Recurrence-risk counselling implication (curation-relevant): for a proband with a confirmed de novo variant and non-mosaic parents, recurrence risk is low but not zero because of the documented mosaic transmission. This is a concrete, evidence-backed counselling point.

Reproductive fitness note: "Most SOX11 variants in our cohort were de novo, in keeping with a severe syndrome that impairs reproductive fitness." [FULL-TEXT p.1267] Reduced fecundity is compounded by the hypogonadotropic hypogonadism itself — a mechanistically elegant explanation for the de novo predominance.

9.3 Population demographics

• Affected populations: no ethnic or ancestral predisposition. Al-Jawahiri explicitly noted "a consistent facial dysmorphology across multiple ethnic groups" [FULL-TEXT p.1265], which is itself a useful cross-population finding.
• Geographic distribution: worldwide; no endemic region. Reporting is skewed by sequencing access — UK (DDD/100kGP) and China (recent case reports) dominate. This is ascertainment bias, not true geographic variation.
• Geographic distribution of specific variants: none. Recurrent variants (p.Lys50Asn, p.Gly47Ser, p.Ala55Thr, p.Trp87Arg, p.Tyr116Cys, p.Arg51*) recur across unrelated populations — consistent with independent de novo mutation at mutable/functionally-critical residues rather than shared ancestry.
• Sex ratio: no sex bias reported (autosomal). Both sexes affected. However, sex profoundly affects ascertainment of the endocrine phenotype: "In males with SOX11 syndrome presentation, genital malformations at birth was reported, but in both sexes delayed puberty was the principal manifestation" [FULL-TEXT p.1268]. Males present earlier (cryptorchidism/micropenis at birth); females typically not until primary amenorrhoea. Curate this as a diagnostic-bias note, not a sex ratio.
• Age distribution: paediatric-dominated in the literature (mean age at examination 9 years, range neonate–23 years). Adults are systematically under-represented — the sole adult cohort (n=35) is mixed-BAFopathy (PMID:38117302). Adult natural history is a major gap.

10. Diagnostics

10.1 Genetic testing (the diagnostic mainstay)

Recommended approach: SOX11-related NDD is a genotype-first diagnosis. There is no biochemical marker and the facial gestalt is explicitly non-specific, so molecular testing is the only reliable route.

Two technical pitfalls to record: 1. Single-exon gene. Exome CNV callers with poor single-exon resolution can miss intragenic SOX11 events. Pair sequencing with CMA or use a CNV-competent WGS pipeline. 2. No splice variants exist. Any reported SOX11 splice-site variant should trigger re-verification.

10.2 Omics-based diagnostics — the SOX11 episignature (clinically deployed)

This is the standout diagnostic tool and belongs prominently in the entry.

Assay: genome-wide DNA methylation on peripheral blood DNA via Illumina Infinium MethylationEPIC array, interpreted against the EpiSign Knowledge Database with an SVM classifier producing an MVP score (0–1).

Performance: "In all steps, the testing samples were correctly clustered with the training samples, further providing evidence of a robust common DNA methylation signature for SOX11." A 224-DMP signature with global hypomethylation; when trained against 38 additional NDD episignatures, "A high MVP score was seen in 10 SOX11 samples with much improved specificity relative to other EpiSign conditions." [FULL-TEXT pp.1265–66]

Clinical uses: - Reclassification of VUS — the primary value, given that 25 of 29 reported SNVs are missense. - Differentiation from BAFopathies — no BAFopathy sample clustered with SOX11. - Diagnostic confirmation in genetically unsolved patients.

[FULL-TEXT p.1269] "It also shows the utility of DNA methylation profiling as a useful biomarker for clinical diagnosis of SOX11-related disorders."

Caveat to record: derived from only 10 cases vs 50 controls — a small training set. Al-Jawahiri acknowledge "a highly sensitive and specific blood-derived episignature with small number of DMPs for SOX11 syndrome, using a relatively small number of patient samples."

Other omics diagnostics: RNA sequencing — no established diagnostic role. Proteomics, metabolomics, liquid biopsy — not applicable / no role.

10.3 Clinical tests

Laboratory tests / biomarkers:

There is no SOX11-specific biochemical or metabolic biomarker. The DNA methylation episignature is the only molecular biomarker.

Imaging studies:

Functional tests: growth-hormone provocative testing; formal smell testing (but note: "Given the neurodevelopmental delay in SOX11 syndrome, formal assessment of olfaction is not possible" in many patients [FULL-TEXT p.1268] — MRI is the practical surrogate); pulmonary/cardiac function testing only as indicated by structural findings.

Electrophysiology: - Audiology — ABR/BAER and behavioural audiometry: essential; SNHL with inner-ear malformation and cochlear nerve deficiency are established features. - EEG: low yield — only 2/38 patients had epilepsy. Indicated only on clinical suspicion. - ERG: consider for cone-rod dystrophy (single case). - EMG/NCS: not indicated.

Biopsy / pathology findings: none — no diagnostic histopathology exists. Do not curate a histopathology section beyond a note that none is established. Immunohistochemistry for SOX11 protein is a mantle-cell-lymphoma diagnostic and has no role here.

10.4 Clinical criteria and differential diagnosis

Standardised diagnostic criteria: none exist. There are no consensus clinical criteria, no DSM/ICD-specific code, and no society guideline. Diagnosis is molecular. The nearest thing to a clinical trigger is Hanker et al.'s proposed triad:

[VERBATIM — PMID:33785884] "We suggest that the combination of Cogan ocular motor apraxia, hypoplastic nails of fifth toes, and developmental delay give the important diagnostic clue for a variant in the SOX11 gene (OMIM 615866, MR 27)."

Al-Jawahiri add: "Our study confirms that SOX11 syndrome should be part of the differential diagnosis of oculomotor apraxia." [FULL-TEXT p.1268]

Differential diagnosis with distinguishing features:

Framing for curators: SOX11 syndrome sits at a four-way nosological crossroads — BAFopathy/CSS, SOXopathy, Pitt-Hopkins-spectrum, and Kallmann/IHH. It has been diagnosed from each of those four starting points. This is the single most important framing statement for the entry, and the episignature is what resolves it.

10.5 Screening

• Newborn screening: not applicable — no biochemical marker, no NBS panel inclusion, no actionable neonatal intervention.
• Carrier screening: not applicable — dominant disorder, no carrier state.
• Cascade screening: indicated. Test the parents of any proband (including deep sequencing for mosaicism) and, if a familial variant is found, at-risk relatives. Justified by the documented mosaic transmission and the mildly-affected-transmitting-parent family.
• Prenatal diagnosis / PGT: available for a known familial variant (see §13).

11. Outcome / Prognosis

11.1 Survival and mortality

• Survival rate (5/10-year, overall): not established. No survival analysis has been published.
• Life expectancy: not established, but the evidence points to near-normal survival in the majority. The disorder is developmental, not degenerative; there is no organ failure in the typical course; and adults into at least their fifth decade are described in the mixed-BAFopathy adult cohort. Al-Jawahiri's cohort spanned neonate–23 years.
• Mortality rate / disease-specific mortality: not established. One documented death in the largest cohort: Al-Jawahiri case 11 (p.Ala176Glu) "died early in the neonatal period. They had cerebellar hypoplasia and microcephaly" [FULL-TEXT p.1267] — i.e. 1/38 (~2.6%) neonatal mortality in that cohort. Treat this as a single observation, not a rate.
• Mouse contrast worth noting: Sox11-null mice are uniformly neonatally lethal from cardiac outflow-tract defects, whereas human heterozygotes usually survive. The species gap is one of dosage (mouse homozygous null vs human heterozygote), and it is why zebrafish became the preferred model (§15).

11.2 Morbidity and function

Quality-of-life measures: no EQ-5D, SF-36, PROMIS, or disease-specific PRO has been administered in a SOX11 cohort. The only standardised instruments used are adaptive-behaviour and autism-trait measures (PMID:37924570). Explicit gap.

11.3 Disease course — complications

Feeding difficulty ± aspiration (may need gastrostomy); epilepsy (~5%, low); progressive scoliosis; progressive high myopia with fundus/retinal changes; hearing loss with limited CI benefit if the cochlear nerve is deficient; pubertal failure with consequent low bone mineral density; infertility; adult obesity and its sequelae; complications of repaired congenital heart disease; cleft-palate sequelae (speech, otitis media); renal complications of CAKUT.

11.4 Recovery potential

No recovery of the neurodevelopmental core. Developmental gains occur with therapy but the underlying static encephalopathy is permanent. Selective, genuine reversibility exists for the endocrine arm: GnRH-pump therapy "restored gonadotropin output within 72 h" [VERBATIM, PMID:42168980], and pubertal induction, GH replacement, and levothyroxine can fully correct their respective deficits. Surgical correction of cleft palate, cardiac lesions, cryptorchidism, and microtia is anatomically effective.

11.5 Prediction

Prognostic factors — with a critical caveat. A domain-based genotype–phenotype correlation is emerging:

[VERBATIM — PMID:38591849, Wu et al., Am J Med Genet A 2024] "Analysis of 56 SOX11 variants showed variants affecting the high-mobility group (HMG) domain were more likely to cause the widest range of organ anomalies." The authors "conclude that thorough clinical examination is warranted for patients carrying pathogenic SOX11 variants affecting the HMG domain, as these variants demonstrate the widest range of organ anomalies."

⚠️ But this correlation is contradicted at the individual level. The most severe outcome reported (neonatal death) occurred with a NON-HMG missense variant (p.Ala176Glu) whose in-vitro transactivation deficit was explicitly milder than that of the PTVs ("A176E impairs SOX11 activity but to a much lesser extent than Y294* or G384Rfs*14"). Therefore:

• In-vitro residual transactivation does NOT predict clinical severity.
• HMG-domain localisation predicts breadth of organ involvement, not severity of outcome.
• Curate this as an explicit KNOWLEDGE_GAP discussion: genotype–phenotype prediction in SOX11 syndrome is not currently reliable at the individual level.

Other prognostic factors: attainment of speech by ~40 months (the 20% who don't have a worse functional trajectory); presence of cerebellar hypoplasia + microcephaly (co-occurred in the one fatal case); presence of major congenital heart disease.

Prognostic biomarkers: none. The episignature is diagnostic, not prognostic — no correlation between MVP score or DMP pattern and clinical severity has been reported. Explicit gap.

12. Treatment

There is no disease-modifying or curative therapy. Management is entirely supportive, symptom-directed, and multidisciplinary. All recommendations below are extrapolated from CSS/BAFopathy management (PMID:23556151, GeneReviews) plus SOX11-specific endocrine and sensory findings; no SOX11-specific clinical practice guideline exists, and no clinical trial has ever been conducted in this disorder.

12.1 Pharmacotherapy

Pharmacogenomics: none. No CPIC guideline, no FDA PGx biomarker, and zero PharmGKB/CPIC records for SOX11 (confirmed via ClinGen: "CPIC/PharmGKB Records: 0/0"). Standard PGx considerations apply only to the general drug classes used (e.g. CYP2D6 for some psychotropics), not to SOX11 itself.

12.2 Advanced therapeutics

12.3 Surgical and interventional

12.4 Supportive and rehabilitative

12.5 Experimental treatments

None. There are ZERO registered clinical trials for SOX11-related neurodevelopmental disorder on ClinicalTrials.gov, the EU CTR, or WHO ICTRP. Do not populate a clinical_trials section; record the absence explicitly as a notes: statement or a KNOWLEDGE_GAP discussion.

12.6 Treatment outcomes

• Response rates: no systematic data. The only quantified therapeutic response in the literature is the GnRH-pump gonadotropin restoration within 72 h (n=1, PMID:42168980).
• Side effects / adverse events: no SOX11-specific safety signal exists; standard class-effect profiles apply (e.g. growth-hormone-associated risks, sex-steroid effects on epiphyseal fusion, gastrostomy complications). No FAERS signal specific to this population.

12.7 Treatment strategy

Algorithm (synthesised — no published guideline exists):

1. At diagnosis — baseline multisystem evaluation. The strongest published recommendation: SOX11-related disorder "mandat[es] comprehensive baseline evaluation" including "endocrine assessment, neurodevelopmental screening, and imaging" (PMID:42168980). Concretely: brain MRI (with dedicated IAC + olfactory + pituitary sequences), audiology, ophthalmology with fundus screening, renal ultrasound, echocardiogram, growth parameters, feeding/nutrition safety assessment, developmental assessment, spine examination.
2. Ongoing (each visit, per CSS GeneReviews): "Measurement of growth parameters; evaluation of nutrition status and safety of oral intake; assessment for new neurologic manifestations"; behavioural assessment (anxiety, ADHD, autism, aggression, self-injury); sleep; developmental/educational progress.
3. Periodic: annual ophthalmology and audiology; dental review at least every 6 months.
4. ⚠️ At ages 11–14 — the pubertal checkpoint. Proactively assess pubertal status (Tanner staging, basal LH/FSH, sex steroids) rather than waiting for referral. 21% of patients have HH, and the intervention window is finite. This is the highest-value, most-often-missed action in the disorder.
5. Adulthood: transition planning; weight/metabolic management; scoliosis and vision surveillance; ongoing hormone replacement.

Combination therapies: hormone replacement is inherently combinatorial (sex steroid ± GH ± levothyroxine); therapy bundles (speech + OT + PT) are standard. Personalised/genotype-guided treatment: not yet actionable. The HMG-domain → broader-organ-involvement correlation (PMID:38591849) is the only genotype-informed recommendation, and it guides screening intensity, not therapy choice. No genotype-guided treatment exists.

13. Prevention

13.1 Primary prevention

Not possible. The disorder arises from de novo germline mutation during gametogenesis/early embryogenesis; there is no modifiable exposure, no vaccine-preventable component, and no risk-factor modification available. The only "primary prevention" available operates at the reproductive-decision level:

• Preimplantation genetic testing (PGT-M) for couples with a known familial SOX11 variant (including a mosaic or mildly-affected parent).
• Prenatal diagnosis (CVS/amniocentesis) for a known familial variant. Available per CSS GeneReviews: "Prenatal and preimplantation genetic testing are available options."

13.2 Secondary prevention (early detection + early intervention)

This is where the real preventive leverage lies: - Comprehensive baseline evaluation at molecular diagnosis (see §12.7) — detects treatable/correctable lesions (HH, GH deficiency, hypothyroidism, cardiac, renal, hearing, vision) before they cause irreversible harm. - Early speech/language intervention and AAC introduction — the ~20% non-verbal rate makes early AAC a preventive measure against permanent communication failure. - Proactive adolescent endocrine screening — prevents the bone-density, growth, and psychosocial consequences of unrecognised pubertal failure. - Cochlear nerve MRI before considering CI — prevents a futile surgery.

13.3 Tertiary prevention (preventing complications in affected individuals)

• Pubertal induction → prevents osteoporosis/low BMD and psychosocial morbidity.
• Weight/nutrition management from childhood → pre-empts the frequent adult obesity.
• Spine surveillance → early scoliosis intervention.
• Ophthalmological surveillance including fundus → prevents avoidable visual loss from progressive myopia/retinopathy.
• Dental review ≥2×/year and annual audiology/ophthalmology (per CSS surveillance).
• Aspiration prevention via feeding-safety assessment.

13.4 Immunization

Not applicable — no vaccine-preventable component. Routine childhood immunisation per standard schedule; no contraindication arises from the disorder.

13.5 Screening and early detection

• Population/newborn screening: not applicable or recommended (no biochemical marker, no NBS panel, no neonatal-actionable intervention).
• Genetic screening: cascade testing of relatives for a known familial variant; parental testing including deep sequencing for mosaicism is specifically warranted given the documented mosaic transmission; PGT-M and prenatal testing as above.
• Risk stratification: the one published stratifier is variant domain — HMG-domain variants warrant the most thorough multi-organ evaluation (PMID:38591849). No validated risk-prediction model or clinical calculator exists.
• Panel-inclusion advocacy as a screening measure: "SOX11 should be included in Kallmann syndrome gene panels" (PMID:42168980) — a concrete, actionable diagnostic-yield recommendation.

13.6 Behavioural interventions

No lifestyle modification prevents the disorder. Post-diagnosis behavioural/lifestyle measures target complication prevention: physical activity and dietary management for weight, sleep hygiene, and behavioural therapy for ASD/ADHD-associated behaviours.

13.7 Counselling

Genetic counselling is a core intervention (NCIT:C15240). Content to convey: 1. Autosomal dominant; ~79–94% de novo. 2. Recurrence risk after a de novo variant is low but NOT zero — parental gonadal/germline mosaicism is documented. 3. Test both parents, and consider deep sequencing for low-level mosaicism. 4. Variable expressivity: an apparently unaffected or minimally-affected parent may be a carrier — the transmitting mother in PMID:33785884 had only hypoplastic 5th toenails. Examine parents' fifth toenails. 5. An affected individual's own offspring risk is 50% — but reproductive fitness is reduced by both ID and hypogonadotropic hypogonadism, and fertility may require assisted reproduction. 6. Prenatal/PGT options; and prenatal cardiovascular evaluation is specifically recommended for fetuses with a known SOX11 variant (PMID:42015706).

13.8 Public health and environmental interventions

Not applicable. No sanitation, vector-control, environmental-remediation, or population health-education intervention is relevant to a de novo Mendelian disorder. The one legitimate public-health-adjacent action is improving access to trio exome/genome sequencing and to episignature testing, which increases diagnostic yield and enables the surveillance benefits above.

13.9 Prophylaxis

No pharmacological or procedural prophylaxis exists. Specifically: no antiseizure prophylaxis is warranted (epilepsy ~5%), and no oncological prophylaxis or tumour surveillance is indicated — the ARID1A AFP/hepatoblastoma protocol does not extend to SOX11.

14. Other Species / Natural Disease

14.1 Taxonomy and orthologous genes

[VERBATIM — PMID:40832700] "Caenorhabditis elegans has a single SoxC protein, SEM-2, which is essential for development. … The equivalent amino acid of SOX11 Y116 is SEM-2 Y160, a residue in the C-terminal tail of the highly conserved DNA-binding domain."

14.2 Breed

Not applicable. No breed-specific SOX11 disorder is recorded; no VBO identifier applies.

14.3 Natural disease in other species

No naturally occurring SOX11 disorder has been reported in any non-human species. There is no OMIA (Online Mendelian Inheritance in Animals) entry for SOX11, no companion-animal or livestock condition, and no wildlife disease. Every animal phenotype in the literature is experimentally induced (targeted deletion, CRISPR, or morpholino).

Veterinary relevance: none. This should be curated as an explicit negative — it is informative that no spontaneous animal model exists, which is why engineered models carry the entire comparative burden.

14.4 Comparative biology

Comparative pathology — cross-species concordance and discordance (high curation value):

Key interpretive points for curation: 1. The mouse over-models the disease. Sox11-null mice die neonatally of cardiac OFT defects and show asplenia and visceral hypoplasia — features absent or very rare in human heterozygotes. The discordance is a dosage difference (homozygous null vs heterozygous LoF), not a species difference in gene function. This is a textbook HUMAN_MODEL_MISMATCH case: model-organism evidence exists, but its translational validity is limited by the zygosity mismatch. Al-Jawahiri's own framing: "The combined human and murine findings indicate that SOX11 has a general role in brain development, rather than a predominant role in the cerebrum or cerebellum." 2. The mouse's lethality created the need for zebrafish. [VERBATIM, PMID:33061816] "Since the homozygous SOX11 mutant mice died soon after birth, no suitable model was available for the study of the pathogenic mechanism of Coffin-Siris syndrome. To solve this problem, we generated two viable homozygous zebrafish mutants." 3. The heterozygous mouse recapitulates the human hearing phenotype well. "A heterozygous knockout mice model had hearing impairment with grossly normal inner ear structures like the two probands reported" [VERBATIM, PMID:35642566] — a rare instance of clean zygosity-matched concordance. 4. The C. elegans het/homozygous dissociation is the cleanest available argument that SOX11[Y116C] is a simple LoF allele and not dominant-negative.

Evolutionary conservation: the HMG DNA-binding domain is deeply conserved across SoxC proteins and across metazoa (human SOX11 Y116 ≡ C. elegans SEM-2 Y160). The SoxC downstream program is also conserved: the hlh-8/Twist axis in C. elegans mirrors the craniofacial role of Twist orthologs in human craniofacial disorders — "whose human counterparts, when mutated, are known to be associated with craniofacial disorders" [VERBATIM, PMID:40832700]. Conservation of the paralogue-based ACMG evidence (SOX10↔SOX11 equivalent residues, §4.4) is another practical manifestation.

14.5 Transmission

Not applicable — genetic disorder. No zoonotic potential, no cross-species susceptibility, no transmission.

15. Model Organisms

15.1 Mouse (Mus musculus) — MGI:98359

Genetic models available: MGI records 11 mutations/alleles — 2 endonuclease-mediated, 8 targeted (knockout/conditional), 1 transgenic — with 88 phenotypes across 6 alleles in 8 genetic backgrounds and 45 phenotype references.

MGI phenotype summary: "homozygous null mice display neonatal lethality with impaired ossification and impaired development of the heart, lung, spleen, stomach, skeleton and pancreas"; "mice homozygous for a different knock-out allele exhibit abnormal nervous system development and complete neonatal lethality."

Key mouse studies:

[VERBATIM — PMID:15254231, Sock et al., Mol Cell Biol 2004;24(15):6635–6644, DOI 10.1128/mcb.24.15.6635-6644.2004] "Sox11-deficient mice died at birth from congenital cyanosis, likely resulting from heart defects. These included ventricular septation defects and outflow tract malformations that ranged from arterial common trunk to a condition known as double outlet right ventricle. Many other organs that normally express Sox11 also exhibited severe developmental defects. We observed various craniofacial and skeletal malformations, asplenia, and hypoplasia of the lung, stomach, and pancreas. Eyelids and the abdominal wall did not close properly in some Sox11-deficient mice. This phenotype suggests a prime function for Sox11 in tissue remodeling and identifies SOX11 as a potentially mutated gene in corresponding human malformation syndromes."

[VERBATIM — PMID:23483698, Wang et al., Dev Dyn 2013;242:638–653] "In this study, we generated a Sox11 floxed allele and a Sox11 null allele in mice using the Cre-loxP technology. … Sox11 null embryos developed small and disorganized brains, accompanied by transient proliferation deficits in NPCs. Deletion of Sox11 in adult NPCs blunted proliferation in the SGZ. … our work provides evidence that Sox11 is required for both embryonic and adult neurogenesis, and identifies potential downstream target genes."

[VERBATIM — PMID:26826126, Huang et al., J Biol Chem 2016;291:7107–7118] "We found that loss of Sox11 led to reduced cell proliferation in the developing mandibular mesenchyme via Cyclin D1, leading to mandibular hypoplasia, which blocks tongue descent. Extensive analyses of gene expression in Sox11 deficiency identified FGF9 as a potential candidate target of Sox11… Finally we show, using in vitro assays, that Sox11 directly regulates the expression of Fgf9 and that application of FGF9 protein to Sox11-deficient palatal shelves restores the rate of BrdU incorporation. Taken together, the palate defects presented in the Sox11 loss mutant mimic the clefting in the Pierre Robin sequence in humans."

[VERBATIM — PMID:29459093, Neirijnck et al., Kidney Int 2018;93:1142–1153] "Deletion of Sox11 in mice causes an extension of the domain expressing Gdnf within rostral regions of the nephrogenic cord and results in duplex kidney formation. On the molecular level SOX11 directly binds and regulates a locus control region of the protocadherin B cluster. At later stages of kidney development, SOX11 becomes restricted to the intermediate segment of the developing nephron where it is required for the elongation of Henle's loop. Finally, mutation analysis in a cohort of patients suffering from CAKUT identified a series of rare SOX11 variants, one of which interferes with the transactivation capacity of the SOX11 protein."

[VERBATIM — PMID:33579706, Chiang et al., Sci Adv 2021] "Usp11 deficiency impairs layer 6 neuron production, delays late-born neuronal migration, and disturbs cognition and anxiety behaviors. Mechanistically, these functions are mediated by a previously unidentified Usp11 substrate, Sox11."

Heterozygous mouse (the zygosity-matched model): per PMID:35642566, "Homozygous ablation of SOX11 in a mouse model resulted in a reduction in sensory neuron survival and decreased axonal growth. A heterozygous knockout mice model had hearing impairment with grossly normal inner ear structures like the two probands reported."

Also cited: Sox11-null mice have small olfactory bulbs (relevant to the Kallmann/anosmia arm) and "generalized reduction in size of the cerebrum and cerebellum" (both via Al-Jawahiri refs 29/34).

IMPC status: the IMPC gene page for MGI:98359 shows 0 significant phenotypes and 0/24 physiological systems tested — Sox11 has not been through the IMPC pipeline (unsurprising given homozygous neonatal lethality). Do not cite IMPC as a phenotype source.

Mouse limitations: homozygous neonatal lethality precludes study of postnatal neurodevelopment, cognition, behaviour, puberty, and adult outcome — i.e. precisely the domains that dominate the human phenotype. Conditional (Cre-loxP) and heterozygous models are the workarounds. The homozygous cardiac/visceral phenotype over-represents what human heterozygotes experience.

15.2 Zebrafish (Danio rerio) — the preferred whole-organism model

[VERBATIM — PMID:33061816, Jia et al., Int J Biol Sci 2020, DOI 10.7150/ijbs.47510] "we generated two viable homozygous zebrafish mutants, sox11a^m/m^ and sox11b^m/m^. We found that the sox11a^m/m^ mutant possessed Coffin-Siris syndrome features. The sox11a^m/m^ mutants exhibited growth deficiency from 3.3 hpf embryos to adulthood. Furthermore, the sox11a^m/m^ mutant also displayed microcephaly, narrow pupillary distance, achondroplasia, and bone deformity in adults. Growth deficiency could be rescued by the injection of sox11a mRNA at the one-cell stage. In addition, the expression levels of genes related to cartilage and bone were downregulated in the sox11a^m/m^ mutant, indicating that sox11a mainly affected the growth and development of zebrafish by regulating the expression of genes related to skeletal development. Our results indicate that sox11a^m/m^ mutant zebrafish offered a potential model system to help with the search for pathogenic mechanisms of human Coffin-Siris syndrome."

[VERBATIM — PMID:25010521, Pillai-Kastoori et al., PLoS Genet 2014, DOI 10.1371/journal.pgen.1004491] "Sox11-deficient zebrafish embryos displayed delayed and abnormal lens formation, coloboma, and a specific reduction in rod photoreceptors, all of which could be rescued by treatment with the Hedgehog pathway inhibitor cyclopamine. We further demonstrate that the elevated Hedgehog signaling in Sox11-deficient zebrafish was caused by a large increase in shha transcription; indeed, suppressing Shha expression rescued the ocular phenotypes of sox11 morphants. Conversely, over-expression of sox11 induced cyclopia… We screened DNA samples from 79 patients with microphthalmia, anophthalmia, or coloboma (MAC) and identified two novel heterozygous SOX11 variants in individuals with coloboma. In contrast to wild type human SOX11 mRNA, mRNA containing either variant failed to rescue the lens and coloboma phenotypes of Sox11-deficient zebrafish, and both exhibited significantly reduced transactivation ability in a luciferase reporter assay."

Also: sox11a/b morpholino knockdown "causes brain abnormalities" (PMID:24886874), and Al-Jawahiri note the ocular malformations "are recapitulated in sox11 null zebrafish, confirming the specificity of the finding."

Strengths: viable homozygous mutants; embryos are optically transparent for ocular phenotyping; mRNA rescue and small-molecule (cyclopamine) rescue are both demonstrated, giving a genuine functional-assay platform for VUS classification; established cross-species mRNA-complementation assay for human SOX11 variants. Limitations: teleost genome duplication (sox11a/sox11b) complicates dosage interpretation; no cognitive/behavioural readout comparable to human ID; no pituitary-gonadal axis readout matching human HH. Database: ZFIN.

15.3 Xenopus

Morpholino knockdown of Sox11: "Knockdown of Sox11 by MO injection resulted in a significant reduction in head area and interpupillary distance compared with controls (both p<0.0001)" (PMID:26543203). Strength: direct, quantitative microcephaly readout — the assay that established microcephaly as a SOX11-LoF consequence. Limitation: morpholino (transient knockdown, off-target concerns); no cognitive readout. Database: Xenbase.

15.4 Caenorhabditis elegans

[VERBATIM — PMID:40832700, Baccas & Liu, G3 2025] "Homozygous, but not heterozygous, sem-2[Y160C] animals exhibit a high rate of embryonic and larval lethality, egg-laying defects, reduced brood size, bivulval phenotype and a low penetrance of hermaphrodite tail abnormalities. Additionally, sem-2[Y160C] animals have reduced expression of hlh-8/Twist, whose human counterparts, when mutated, are known to be associated with craniofacial disorders. All the phenotypes observed in sem-2[Y160C] animals resemble SEM-2 loss-of-function phenotypes, suggesting that SOX11[Y116C] is a loss-of-function, recessive mutation that likely causes defects due to haploinsufficiency. Our work suggests that using C. elegans as a model system to analyze the molecular effects of point mutations associated with craniofacial defects has the potential for unraveling the underlying mechanisms."

Strength: the only SoxC system with no paralogous redundancy, enabling clean allele-series analysis; humanised point-mutation knock-in (Y116C ≡ Y160C) at low cost; establishes the LoF/non-dominant-negative mechanism. Limitation: no nervous-system, craniofacial, ocular, or endocrine homology to human disease; results are about protein-level mechanism, not organ pathology. Database: WormBase.

15.5 Human cellular / in vitro models

SOX11⁺/⁻ isogenic human embryonic stem cells (the best human-relevant model):

[VERBATIM — PMID:31035284] "we describe the generation of SOX11+/- heterozygous human embryonic stem cell (hESC) lines by CRISPR/Cas9 genome engineering. SOX11 haploinsufficiency impaired the generation of neurons and resulted in a proliferation/differentiation imbalance of neural precursor cells and enhanced neuronal cell death. Using the SOX11+/- hESC model we provide for the first time experimental evidence that SOX11 haploinsufficiency is sufficient to impair key processes of human neurodevelopment, giving a first insight into the pathophysiology of CSSLS and SOX11 function in human neurodevelopment."

Strengths: correct species, correct zygosity (heterozygous — matching human disease), isogenic control. The single most translationally valid model available. Limitations: 2D culture; no circuit-level, behavioural, or systemic readout; does not model non-neural organs.

Other cellular systems: - HeLa / HEK293T transient transfection + GDF5-promoter luciferase — the standard SOX11 variant functional assay across three labs (PMID:26543203, 35341651, 35938035). Method detail: GDF5 promoter −448/+319 (NM_000557.3, GRCh37/hg19) in pGL3-basic; p3xFLAG-CMV-14 SOX11 expression construct; pRL-SV40 internal control; PicaGene Dual Sea Pansy; significance threshold P<.016 (Bonferroni for 3 comparisons); anti-FLAG M2 HRP immunoblot for protein-level confirmation. This is a directly implementable assay for VUS reclassification. - GT1-1 immortalised GnRH neurons — SOX11 knockdown reduces GNRH1 expression and GnRH secretion (PMID:21527504). - iPSC-derived GnRH neurons (GNRH1-TdTomato reporter) — SOX11 was not enriched (Lund et al., Dis Model Mech 2020;13(3):dmm040105) — a negative human result that conflicts with the mouse GnRH-neuron data. Curate as a HUMAN_MODEL_MISMATCH. - Human fetal tissue RNAscope ISH — Carnegie stages 20, 21, 23 (§7.5). Not a "model" but the key human spatial-expression evidence. - Morphogen-guided neocortical organoids — an emerging platform for NDD modelling (PMID:40950130, bioRxiv 2025, preprint).

15.6 Induced (non-genetic) models

None relevant. No drug-induced, surgical, or environmental-manipulation model of SOX11 syndrome exists (consistent with the absence of any environmental aetiology).

15.7 Research applications and resources

Model databases: MGI (MGI:98359), IMPC (untested), IMSR/KOMP/EuMMCR/EMMA/MMRRC (allele sourcing), ZFIN, Xenbase, WormBase, Alliance of Genome Resources, Cellosaurus (for the SOX11⁺/⁻ hESC lines — deposit status not confirmed).

Appendix A — Recommended dismech curation priorities

1. disease_term: MONDO:0100626 (not MONDO:0014376 — see §1.2). Put MONDO:0014376 + OMIM:615866 in mappings.
2. Model the SOX11↔BAF relationship explicitly — germline: SOX11 is downstream of PAX6–BAF; somatic (neuroblastoma): SOX11 is upstream of SWI/SNF. This bidirectionality is the reason for the CSS9 misnomer and merits a notes: treatment.
3. Curate the episignature as a diagnostic biomarker, not as a mechanism. 224 DMPs, global hypomethylation, 10 cases vs 50 controls, MVP score.
4. Consider conforms_to against existing modules — candidate matches worth evaluating:
5. pharyngeal_arch_patterning_serial_homology — the cleft palate + mandibular hypoplasia + microtia + external/inner ear bundle is a plausible but non-canonical fit: the mouse mechanism (Cyclin D1/FGF9 mesenchymal proliferation → mandibular hypoplasia → tongue obstruction → cleft) is a proliferation-and-obstruction mechanism, not the module's neural-crest arch-identity or ribosomopathy mechanism. Evaluate carefully before asserting conformance.
6. sensorineural_hair_cell_loss — likely a poor fit. SOX11 SNHL arises from cochlear nerve aplasia with a structurally normal cochlea, i.e. a retrocochlear/neural lesion, not hair-cell mechanotransduction failure. Prefer a disorder-specific node.
7. renal_cystogenesis — not a fit. SOX11 causes duplex/malpositioned kidney (CAKUT branching defects), not cAMP-driven tubular cystogenesis.
8. No existing module covers "hypogonadotropic hypogonadism as a final common pathway." Given that HH recurs across SOX2, SOX10, CHD7, FGFR1, ANOS1, and now SOX11, a new hypogonadotropic_hypogonadism_gnrh_axis module is a genuinely well-motivated proposal — but that is a separate PR, not part of this entry.
9. Record three HUMAN_MODEL_MISMATCH discussions (not generic KNOWLEDGE_GAP — evidence exists but translational validity is the open question):
10. Sox11-null mouse cardiac OFT lethality and asplenia/visceral hypoplasia are absent in human heterozygotes (zygosity mismatch).
11. SOX11 is enriched in mouse hypothalamic GnRH neurons and stimulates GnRH in vitro, but was not enriched in human iPSC-derived GnRH neurons — leaving the human hypothalamic mechanism unresolved.
12. Zebrafish sox11a/sox11b paralogy means homozygous fish mutants model a dosage state with no human equivalent.
13. Record KNOWLEDGE_GAP discussions for: no prevalence estimate; no natural-history study; no QoL instrument; no clinical trial; no prognostic biomarker; in-vitro transactivation does not predict clinical severity (p.Ala176Glu paradox); no non-coding/regulatory SOX11 variants reported despite a documented super-enhancer landscape; adult natural history unknown.
14. Do not import from Coffin-Siris syndrome: the ARID1A AFP/hepatoblastoma surveillance; ORPHA:1465 prevalence figures; "coarse facies" as a core feature.
15. Verify every ontology ID in this report with OAK before committing — and specifically do NOT use HP:0013272 (see discrepancy D1).
16. Fetch and validate every PMID: run just fetch-reference PMID:XXXX then just validate-references. [PARAPHRASE]-marked content must not be used as a snippet.

Appendix B — Master citation list

Sources: Al-Jawahiri 2022 — Genetics in Medicine · Al-Jawahiri 2022 open-access PDF (White Rose) · PubMed 35341651 · PubMed 24886874 · PubMed 26543203 · PubMed 37558216 · Pasquetti 2024 — Clinical Genetics · PubMed 39290158 · PubMed 42168980 · PubMed 37924570 · PubMed 39333428 · Chinese CSS9 functional analysis — PMC9354949 · Frontiers in Genetics 2022 · PubMed 33785884 · PubMed 36369738 · PubMed 35642566 · PubMed 38591849 · CSS9 ophthalmology review — PMC12417530 · PubMed 29437512 · PubMed 28787104 · PubMed 42015706 · PubMed 35126043 · Coffin-Siris genotype-phenotype 208 individuals — PMC8233770 · Coffin-Siris Syndrome — GeneReviews · PubMed 31035284 · PubMed 15254231 · PubMed 33061816 · PubMed 25010521 · Neirijnck 2018 — Kidney International · PubMed 29459093 · PubMed 40832700 · PubMed 33579706 · PubMed 36882421 · Sox11 cleft palate — SAGE · SoxC in development and cancer — PMC2862366 · Cardiac outflow tract Sox4/Sox11 — Springer · Sox12 deletion nonreciprocal redundancy — PMC2493363 · SoxC overlapping expression — Nucleic Acids Research · OMIM 600898 — SOX11 · MedGen — Coffin-Siris syndrome 9 · NCBI Gene 6664 — SOX11 · HGNC REST — SOX11 · MONDO:0100626 via EBI OLS4 · MONDO:0014376 via EBI OLS4 · ClinGen SOX11 dosage sensitivity · ClinGen SOX11 gene curations · HPO annotations for OMIM:615866 · MGI:98359 — mouse Sox11 · IMPC — Sox11 · gnomAD v4.0 gene constraint documentation · SOX11 is a mantle cell lymphoma oncogene — Blood · SOX11:SMARCA4 complex in MCL — Blood Cancer Journal · Adult Coffin-Siris phenotype (Europe PMC 38117302)